Warner E F, Guneri D, O'Connell M A, MacDonald C J, Waller Z A E
School of Chemistry, Pharmacy and Pharmacology, University of East Anglia, Norwich, Norfolk, UK.
UCL School of Pharmacy, London, UK.
Commun Chem. 2025 Jan 6;8(1):5. doi: 10.1038/s42004-024-01387-w.
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a key regulator of cell detoxification, which maintains homoeostasis in healthy cells and promotes chemoresistance in cancer cells. Controlling the expression of this transcription factor is therefore of great interest. There are many compounds that have been shown to induce Nrf2 expression, but ligands that can inhibit Nrf2 are scant. Herein we characterise an i-motif-forming sequence downstream of the Nrf2 promoter, which we hypothesised may regulate the expression of the gene. The Nrf2 i-motif was found to be stable at near-physiological conditions. We identified small molecule ligands that interact with this i-motif structure and one significantly upregulated Nrf2 mRNA expression, and one ligand reduced Nrf2 mRNA expression in human cancer cells. This is the first example of controlling the promoter of Nrf2 by targeting DNA structures and offers an alternative mode of action for the development of compounds to improve the chemotherapeutic responsiveness of existing treatments for cancer.
核因子(红系衍生2)样2(Nrf2)是细胞解毒的关键调节因子,它在健康细胞中维持体内平衡,并促进癌细胞的化疗耐药性。因此,控制这种转录因子的表达备受关注。已有许多化合物被证明可诱导Nrf2表达,但能够抑制Nrf2的配体却很少。在此,我们对Nrf2启动子下游形成i-基序的序列进行了表征,我们推测该序列可能调控该基因的表达。发现Nrf2 i-基序在接近生理条件下是稳定的。我们鉴定出了与这种i-基序结构相互作用的小分子配体,其中一种显著上调了Nrf2 mRNA表达,而另一种配体则降低了人癌细胞中Nrf2 mRNA的表达。这是通过靶向DNA结构控制Nrf2启动子的首个实例,并为开发化合物提供了一种替代作用模式,以提高现有癌症治疗方法的化疗反应性。